Matches in SemOpenAlex for { <https://semopenalex.org/work/W1618072806> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W1618072806 endingPage "547" @default.
- W1618072806 startingPage "547" @default.
- W1618072806 abstract "Previous reports regarding the cutaneous adverse events of epidermal growth factor receptor inhibitors are mostly limited to small case reports and case series, mainly involving Caucasian patients.We describe the trends in the clinical presentation of Asian patients who had cutaneous adverse events induced by epidermal growth factor receptor inhibitors and to explore the relationship between skin adverse events and tumor response.From 2006 to 2010, medical records of Thai patients with non-small cell lung cancer receiving epidermal growth factor receptor inhibitors were retrieved and analyzed.In all, 99 patients were reviewed and analyzed. Erlotinib and gefitinib were commenced in 75 (75.8%) and 24 (24.2%) patients, respectively. Cutaneous adverse events occurred in 43 (57.3%) patients receiving erlotinib and in 15 (62.5%) patients receiving gefitinib. The most common adverse event was xerosis (52.5%). Less common adverse events included papulo-pustular eruption (27.3%), erythematous maculopapular rash (11.1%), mucositis (6.7%), paronychia (5.1%), and trichomegaly (2%). Elderly patients had a higher occurrence of xerosis. The presence of cutaneous adverse events was significantly higher in subjects who had a tumor response.The limitations of study include its retrospective nature, and the initial screening of cutaneous adverse events was done by non-dermatologists.Cutaneous adverse events due to epidermal growth factor receptor inhibitors are not uncommon in the Asian population. We found a positive correlation between the occurrences of cutaneou adverse events and tumor response supporting the view that they are surrogate markers for therapeutic response." @default.
- W1618072806 created "2016-06-24" @default.
- W1618072806 creator A5015240055 @default.
- W1618072806 creator A5021681334 @default.
- W1618072806 creator A5068372527 @default.
- W1618072806 date "2015-01-01" @default.
- W1618072806 modified "2023-10-13" @default.
- W1618072806 title "Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases" @default.
- W1618072806 doi "https://doi.org/10.4103/0378-6323.157448" @default.
- W1618072806 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25994883" @default.
- W1618072806 hasPublicationYear "2015" @default.
- W1618072806 type Work @default.
- W1618072806 sameAs 1618072806 @default.
- W1618072806 citedByCount "15" @default.
- W1618072806 countsByYear W16180728062015 @default.
- W1618072806 countsByYear W16180728062016 @default.
- W1618072806 countsByYear W16180728062017 @default.
- W1618072806 countsByYear W16180728062018 @default.
- W1618072806 countsByYear W16180728062019 @default.
- W1618072806 countsByYear W16180728062020 @default.
- W1618072806 countsByYear W16180728062022 @default.
- W1618072806 countsByYear W16180728062023 @default.
- W1618072806 crossrefType "journal-article" @default.
- W1618072806 hasAuthorship W1618072806A5015240055 @default.
- W1618072806 hasAuthorship W1618072806A5021681334 @default.
- W1618072806 hasAuthorship W1618072806A5068372527 @default.
- W1618072806 hasBestOaLocation W16180728061 @default.
- W1618072806 hasConcept C121608353 @default.
- W1618072806 hasConcept C126322002 @default.
- W1618072806 hasConcept C16005928 @default.
- W1618072806 hasConcept C197934379 @default.
- W1618072806 hasConcept C2777506169 @default.
- W1618072806 hasConcept C2778087573 @default.
- W1618072806 hasConcept C2778168870 @default.
- W1618072806 hasConcept C2778169587 @default.
- W1618072806 hasConcept C2778496288 @default.
- W1618072806 hasConcept C2778570526 @default.
- W1618072806 hasConcept C2779438470 @default.
- W1618072806 hasConcept C2780580887 @default.
- W1618072806 hasConcept C29730261 @default.
- W1618072806 hasConcept C71924100 @default.
- W1618072806 hasConceptScore W1618072806C121608353 @default.
- W1618072806 hasConceptScore W1618072806C126322002 @default.
- W1618072806 hasConceptScore W1618072806C16005928 @default.
- W1618072806 hasConceptScore W1618072806C197934379 @default.
- W1618072806 hasConceptScore W1618072806C2777506169 @default.
- W1618072806 hasConceptScore W1618072806C2778087573 @default.
- W1618072806 hasConceptScore W1618072806C2778168870 @default.
- W1618072806 hasConceptScore W1618072806C2778169587 @default.
- W1618072806 hasConceptScore W1618072806C2778496288 @default.
- W1618072806 hasConceptScore W1618072806C2778570526 @default.
- W1618072806 hasConceptScore W1618072806C2779438470 @default.
- W1618072806 hasConceptScore W1618072806C2780580887 @default.
- W1618072806 hasConceptScore W1618072806C29730261 @default.
- W1618072806 hasConceptScore W1618072806C71924100 @default.
- W1618072806 hasIssue "5" @default.
- W1618072806 hasLocation W16180728061 @default.
- W1618072806 hasLocation W16180728062 @default.
- W1618072806 hasOpenAccess W1618072806 @default.
- W1618072806 hasPrimaryLocation W16180728061 @default.
- W1618072806 hasRelatedWork W1991551364 @default.
- W1618072806 hasRelatedWork W2015104488 @default.
- W1618072806 hasRelatedWork W2134157108 @default.
- W1618072806 hasRelatedWork W2184487997 @default.
- W1618072806 hasRelatedWork W2254126652 @default.
- W1618072806 hasRelatedWork W2280113021 @default.
- W1618072806 hasRelatedWork W2348666640 @default.
- W1618072806 hasRelatedWork W2363852307 @default.
- W1618072806 hasRelatedWork W2418692205 @default.
- W1618072806 hasRelatedWork W3147989365 @default.
- W1618072806 hasVolume "81" @default.
- W1618072806 isParatext "false" @default.
- W1618072806 isRetracted "false" @default.
- W1618072806 magId "1618072806" @default.
- W1618072806 workType "article" @default.